Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.

@article{Chiron2000StiripentolIS,
  title={Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. STICLO study group.},
  author={Catherine Chiron and Michael C Marchand and Agn{\`e}s Tran and Elisabeth Rey and Philippe D'Athis and Julien Vincent and Olivier Dulac and G{\'e}rard Pons},
  journal={Lancet},
  year={2000},
  volume={356 9242},
  pages={1638-42}
}
BACKGROUND Stiripentol is an inhibitor of cytochrome P450 that showed antiepileptic efficacy in severe myoclonic epilepsy in infancy (SMEI) in association with clobazam and valproate in an open study. To confirm these results, 41 children with SMEI were included in a randomised, placebo-controlled, add-on trial. METHODS After a baseline period of 1 month, placebo (n=20) or stiripentol (n=21) was added to valproate and clobazam during a double-blind period of 2 months. Patients then received… CONTINUE READING
Highly Influential
This paper has highly influenced 14 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
115 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 115 extracted citations

Similar Papers

Loading similar papers…